View by Specialty

Trending

AdobeStock_Carrots_1200x630
November 18, 2024
1 min read
Save

CDC: 1 dead in multistate outbreak of E. coli linked to organic carrots

Hematology News

SPONSORED CONTENT
Save
SPONSORED CONTENT
December 26, 2019
3 min read
Save

New gene therapy appears safe, feasible for sickle cell disease

New gene therapy appears safe, feasible for sickle cell disease

ORLANDO — Significant induction of fetal hemoglobin after the infusion of CD34-positive cells occurred among a small cohort of patients with sickle cell disease, according to data from a phase 1 gene therapy feasibility study presented at ASH Annual Meeting and Exposition.

SPONSORED CONTENT
December 23, 2019
1 min read
Save

FDA approves first generic versions of apixaban

FDA approves first generic versions of apixaban

The FDA announced it approved two applications for the first generic versions of apixaban tablets to reduce risk for stroke and systemic embolism in patients with nonvalvular atrial fibrillation.

Trending

AdobeStock_Carrots_1200x630
November 18, 2024
1 min read
Save

CDC: 1 dead in multistate outbreak of E. coli linked to organic carrots

SPONSORED CONTENT
December 23, 2019
4 min read
Save

Fragmentation of care common among young adults with sickle cell disease

Fragmentation of care common among young adults with sickle cell disease

ORLANDO — Young adults with sickle cell disease experienced fragmentation of health care during the transition period after childhood, according to the results of a retrospective study presented at ASH Annual Meeting and Exposition.

SPONSORED CONTENT
December 23, 2019
9 min watch
Save

VIDEO: Efgartigimod safe, effective in primary immune thrombocytopenia

VIDEO: Efgartigimod safe, effective in primary immune thrombocytopenia

ORLANDO — A 3-week treatment cycle of efgartigimod, a neonatal Fc receptor antagonist, was well tolerated and effective in patients with primary immune thrombocytopenia, according to phase 2 data presented at the ASH Annual Meeting and Exposition.

SPONSORED CONTENT
December 23, 2019
2 min read
Save

Hemophilia A patients ‘highly satisfied’ after switching to emicizumab

ORLANDO — Patients with hemophilia A who had higher annual bleeding rates and poor adherence to infusion-based prophylaxis were more likely to switch treatment to emicizumab and were “highly satisfied with this switch,” according to researchers at the ASH Annual Meeting and Exposition.

SPONSORED CONTENT
December 22, 2019
2 min read
Save

ASH presents Scholar Awards to fellows, junior faculty

ASH announced the recipients of its 2019 Scholar Awards.

SPONSORED CONTENT
December 20, 2019
4 min watch
Save

VIDEO: Apixaban demonstrates benefit over other anticoagulation treatments

VIDEO: Apixaban demonstrates benefit over other anticoagulation treatments

ORLANDO — Apixaban reduced the risk for recurrent venous thromboembolism compared with low-molecular-weight heparin and warfarin, according to results of a large epidemiology study presented at the ASH Annual Meeting and Exposition.

SPONSORED CONTENT
December 20, 2019
3 min watch
Save

VIDEO: Aspirin linked to bleeding events in patients receiving direct oral anticoagulants

VIDEO: Aspirin linked to bleeding events in patients receiving direct oral anticoagulants

ORLANDO — In this video at the ASH Annual Meeting and Exposition, Thein H. Oo, MD, FRCPE, FACP, reviews a study that showed the addition of aspirin to direct oral anticoagulants for venous thromboembolism or non-valvular atrial fibrillation was linked to an increase in bleeding events.

SPONSORED CONTENT
December 19, 2019
2 min watch
Save

VIDEO: Crizanlizumab may reduce hospitalization in sickle cell disease

VIDEO: Crizanlizumab may reduce hospitalization in sickle cell disease

ORLANDO — Julie Kanter, MD, from the division of hematology-oncology at the University of Alabama-Birmingham, discussed the first-ever targeted FDA-approved drug for sickle cell disease, crizanlizumab, in a video at the ASH Annual Meeting and Exposition.

SPONSORED CONTENT
December 16, 2019
1 min read
Save

UK authority clears Roche acquisition of Spark

The U.K. Competition and Markets Authority has cleared Roche’s pending acquisition of Spark Therapeutics, ruling the deal would not negatively affect competition, according to a press release.

View more
Healio Minute Subscribe to Healio Minute emails You're now subscribed to Healio Minute Emails
Healio Minute Subscribe to Healio Minute emails You're now subscribed to Healio Minute Emails